Replies to post #49 on Mallinckrodt Plc (MNKT)

[elbiatcho1]

The company is still a decent buy, just don't rely on Acthar.
Licensing of Synacthen should put a damper on revs, but I don't know if there is a timetable for that to occur.

Possibly MNK has something sneaky up their sleeve, quick to pay off the $100M fine which isn't all THAT much (10% of Acthar revenue).
Maybe MNK just wanted to get FDA off their backs?

It will take time for recovery and the (somewhat) re-organzation towards the hospital field is very long-term positive. The other acquisitions will also offset Acthar diminishing returns if Synacthen is licensed.

Do you really think it is going lower or is that just wishful thinking?

Sarcasm mixed in with unknown timetables and social pressure.
I personally don't want it to go lower.

I'm still long in this, no buys no sells since acq. Kind of bites my average shot up to $49.



As Mallinckrodt is the only company that gets cocaine legally, how can one say no?
http://www.nytimes.com/1988/07/01/business/how-coca-cola-obtains-its-coca.html

The cocaine that Stepan derives from the plants is sold exclusively to Mallinckrodt. An official for that company who asked not to be named said, ''We purchase a crude extract and purify it further into one chemical form, cocaine hydrochloride U.S.P.''